Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABP 1019
- Development stage
- Phase 2
- Lead developer
- Shanghai Aibo Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABP 1019 is an orally bioavailable, small-molecule multi-target tyrosine kinase inhibitor (TKI) developed by Shanghai Aibo Pharmaceutical Technology. It is designed to inhibit a broad spectrum of kinases involved in tumor growth, angiogenesis, and metastasis, including Epidermal Growth Factor Receptor (EGFR), Fibroblast Growth Factor Receptors 1-4 (FGFR1-4), Vascular Endothelial Growth Factor Receptors 1-3 (VEGFR1-3), RET, and Platelet-Derived Growth Factor Receptor alpha (PDGFR-α). The drug is currently being evaluated in Phase I/II clinical trials for the treatment of various advanced solid tumors that have progressed on standard therapy, including glioma, pancreatic cancer, osteosarcoma, and small cell lung cancer, as well as brain metastases. Pharmacokinetic studies indicate a half-life of approximately 15–30 hours with linear pharmacokinetics.
- Other names
- ABP1019ABP-1019ABP 1019ABP1019AABP-1019AABP 1019A
02
Targets
EGFR (Epidermal growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on ABP 1019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABP 1019.